Clinical Trials Browser

Phase 3 × osimertinib × Thoracic × Clear all

Carcinoma, Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

NSCLC Patients With Brain Metastasis

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Stage IB-IIIA Non-small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Locally Advanced or Metastatic Non-squamous NSCLC

Locally Advanced or Metastatic EGFR T790M+ NSCLC

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms, Neoplasm, Residual

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Clinical Trials

TROPION-Lung15

LAURA

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

MARIPOSA

SYNSTAR-02

RELAY

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

COMPEL

ADAURA2

FLAURA

ADAURA

A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

TROPION-Lung14

FLAURA2

SACHI

A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

CAURAL

ERIS

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M